November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Rachel Riechelmann: Low dose Everolimus for patients with Neuroendocrine tumors
Nov 13, 2024, 08:56

Rachel Riechelmann: Low dose Everolimus for patients with Neuroendocrine tumors

Rachel RiechelmannDirector of the Clinical Oncology Department and Professor at AC Camargo Cancer Center, shared an article on X:

“Low dose (LD: ~ 5mg/d) Everolimus similar time to treatment failure to high dose (HD) for pts with Neuroendocrine tumors.

Our retrospective multi center data.

Less dose, less tox, less cost.

We need more dose optimization studies in oncology!”

Rachel Riechelmann: Low dose Everolimus for patients with Neuroendocrine tumors

The Efficacy of a Lower Dose of Everolimus in Patients with Advanced Neuroendocrine Tumors.

Authors: Rodrigo G. Taboada, et al.

Rachel Riechelmann: Low dose Everolimus for patients with Neuroendocrine tumors

 

 

Dr. Rachel Riechelmann is the Director of the Clinical Oncology Department and Professor at AC Camargo Cancer Center, Sao Paulo, Brazil and also serves as the President of the Brazilian GI Tumors Group (GTG). Prof. Riechelmann is a member of ESMO Scientific Committees (Colorectal and NET), Latin American Society of GI Oncology (SLAGO), the European Society of Neuroendocrine Tumors Advisory Board and Chair – GI LACOG (Latin American Cooperative Oncology Group).